Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea flag South Korea · Delayed Price · Currency is KRW
149,900
-2,000 (-1.32%)
Last updated: Apr 29, 2026, 2:20 PM KST

Daewoong Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Operating Revenue
1,570,8911,422,6831,375,3291,280,0921,152,976
Upgrade
Other Revenue
--0-0-0-0
Upgrade
Revenue
1,570,8911,422,6831,375,3291,280,0921,152,976
Upgrade
Revenue Growth (YoY)
10.42%3.44%7.44%11.03%9.24%
Upgrade
Cost of Revenue
748,359688,516688,221641,997609,227
Upgrade
Gross Profit
822,532734,168687,108638,095543,749
Upgrade
Selling, General & Admin
427,581397,216376,109366,091315,434
Upgrade
Research & Development
180,315171,290171,573163,602127,269
Upgrade
Amortization of Goodwill & Intangibles
3,9894,6761,9191,9632,072
Upgrade
Other Operating Expenses
5,1164,4764,3824,2973,554
Upgrade
Operating Expenses
627,024588,929565,990542,297455,020
Upgrade
Operating Income
195,508145,238121,11895,79788,729
Upgrade
Interest Expense
-12,475-6,986-13,603-8,406-10,248
Upgrade
Interest & Investment Income
2,5965,0943,0994,1352,569
Upgrade
Earnings From Equity Investments
46,141-23,15329,977-374.54257.52
Upgrade
Currency Exchange Gain (Loss)
-10,0456,261-1,705-40.313,246
Upgrade
Other Non Operating Income (Expenses)
-10,811-25,331-13,423-43,639-69,962
Upgrade
EBT Excluding Unusual Items
210,913101,123125,46247,47314,591
Upgrade
Gain (Loss) on Sale of Investments
-4,506-28,614130.67-4,1718,308
Upgrade
Gain (Loss) on Sale of Assets
79.96-465.97-1,221246.4-1,029
Upgrade
Asset Writedown
-14,654-15,492-2,372-5,219-2,109
Upgrade
Pretax Income
191,83356,550121,99938,33019,761
Upgrade
Income Tax Expense
-1,07633,2041,996-833.51-10,323
Upgrade
Earnings From Continuing Operations
192,90923,347120,00339,16330,084
Upgrade
Minority Interest in Earnings
2,9471,3881,7363,076-5,578
Upgrade
Net Income
195,85624,735121,73942,24024,506
Upgrade
Net Income to Common
195,85624,735121,73942,24024,506
Upgrade
Net Income Growth
691.83%-79.68%188.21%72.37%92.15%
Upgrade
Shares Outstanding (Basic)
1212111111
Upgrade
Shares Outstanding (Diluted)
1212111111
Upgrade
Shares Change (YoY)
-0.71%3.21%0.59%3.21%
Upgrade
EPS (Basic)
17021.642149.6510655.613815.952226.87
Upgrade
EPS (Diluted)
17021.642149.6510655.613815.952226.87
Upgrade
EPS Growth
691.83%-79.83%179.24%71.36%86.18%
Upgrade
Free Cash Flow
-42,329-103,65326,67152,98810,906
Upgrade
Free Cash Flow Per Share
-3678.75-9008.372334.474786.97991.08
Upgrade
Dividend Per Share
600.000----
Upgrade
Gross Margin
52.36%51.60%49.96%49.85%47.16%
Upgrade
Operating Margin
12.45%10.21%8.81%7.48%7.70%
Upgrade
Profit Margin
12.47%1.74%8.85%3.30%2.13%
Upgrade
Free Cash Flow Margin
-2.70%-7.29%1.94%4.14%0.95%
Upgrade
EBITDA
246,580194,217164,915135,492129,613
Upgrade
EBITDA Margin
15.70%13.65%11.99%10.59%11.24%
Upgrade
D&A For EBITDA
51,07248,97843,79739,69540,883
Upgrade
EBIT
195,508145,238121,11895,79788,729
Upgrade
EBIT Margin
12.45%10.21%8.81%7.48%7.70%
Upgrade
Effective Tax Rate
-58.72%1.64%--
Upgrade
Advertising Expenses
83,36673,83679,24580,58759,081
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.